The tumor-derived cytokine endothelial-monocyte-activating polypeptide-II (EMAP-II) weakens the blood–tumor barrier, has antitumor activity, and, in combination with TMZ, suppresses the malignant behavior of human GBM stem cells in vitro and in vivo [38,39,40]. This evidence concerns the gene AIMP1 and neoplasm.